ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:ZEG • GB0009895292

160.7 EUR
+0.95 (+0.59%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

5

Overall ZEG gets a fundamental rating of 5 out of 10. We evaluated ZEG against 55 industry peers in the Pharmaceuticals industry. While ZEG has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, ZEG is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • ZEG had positive earnings in the past year.
  • In the past year ZEG had a positive cash flow from operations.
  • Each year in the past 5 years ZEG has been profitable.
  • Each year in the past 5 years ZEG had a positive operating cash flow.
ZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFZEG.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

1.2 Ratios

  • ZEG's Return On Assets of 8.21% is fine compared to the rest of the industry. ZEG outperforms 63.64% of its industry peers.
  • ZEG's Return On Equity of 20.48% is fine compared to the rest of the industry. ZEG outperforms 65.45% of its industry peers.
  • ZEG has a better Return On Invested Capital (14.42%) than 69.09% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ZEG is below the industry average of 14.21%.
  • The last Return On Invested Capital (14.42%) for ZEG is above the 3 year average (11.62%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.21%
ROE 20.48%
ROIC 14.42%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ZEG.DE Yearly ROA, ROE, ROICZEG.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

  • With a decent Profit Margin value of 16.17%, ZEG is doing good in the industry, outperforming 65.45% of the companies in the same industry.
  • In the last couple of years the Profit Margin of ZEG has grown nicely.
  • ZEG has a Operating Margin (24.34%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of ZEG has grown nicely.
  • ZEG's Gross Margin of 81.90% is amongst the best of the industry. ZEG outperforms 85.45% of its industry peers.
  • In the last couple of years the Gross Margin of ZEG has remained more or less at the same level.
Industry RankSector Rank
OM 24.34%
PM (TTM) 16.17%
GM 81.9%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
ZEG.DE Yearly Profit, Operating, Gross MarginsZEG.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

4

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ZEG is still creating some value.
  • The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for ZEG has been increased compared to 5 years ago.
  • The debt/assets ratio for ZEG is higher compared to a year ago.
ZEG.DE Yearly Shares OutstandingZEG.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
ZEG.DE Yearly Total Debt VS Total AssetsZEG.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 6.14 indicates that ZEG is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.14, ZEG belongs to the top of the industry, outperforming 81.82% of the companies in the same industry.
  • ZEG has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as ZEG would need 3.41 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.41, ZEG is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
  • A Debt/Equity ratio of 0.61 indicates that ZEG is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.61, ZEG perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 3.41
Altman-Z 6.14
ROIC/WACC1.58
WACC9.13%
ZEG.DE Yearly LT Debt VS Equity VS FCFZEG.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.3 Liquidity

  • A Current Ratio of 0.88 indicates that ZEG may have some problems paying its short term obligations.
  • ZEG has a Current ratio of 0.88. This is amonst the worse of the industry: ZEG underperforms 83.64% of its industry peers.
  • ZEG has a Quick Ratio of 0.88. This is a bad value and indicates that ZEG is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of ZEG (0.69) is worse than 76.36% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.69
ZEG.DE Yearly Current Assets VS Current LiabilitesZEG.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 20.61% over the past year.
  • Measured over the past years, ZEG shows a quite strong growth in Earnings Per Share. The EPS has been growing by 18.59% on average per year.
  • Looking at the last year, ZEG shows a quite strong growth in Revenue. The Revenue has grown by 13.52% in the last year.
  • Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%

3.2 Future

  • ZEG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.37% yearly.
  • ZEG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.20% yearly.
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ZEG.DE Yearly Revenue VS EstimatesZEG.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
ZEG.DE Yearly EPS VS EstimatesZEG.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

3

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 20.76 indicates a rather expensive valuation of ZEG.
  • The rest of the industry has a similar Price/Earnings ratio as ZEG.
  • ZEG's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.93.
  • The Price/Forward Earnings ratio is 17.94, which indicates a rather expensive current valuation of ZEG.
  • ZEG's Price/Forward Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 27.77. ZEG is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 20.76
Fwd PE 17.94
ZEG.DE Price Earnings VS Forward Price EarningsZEG.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ZEG is valued a bit more expensive than 67.27% of the companies in the same industry.
  • ZEG's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. ZEG is more expensive than 61.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF 61.42
EV/EBITDA 29.47
ZEG.DE Per share dataZEG.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of ZEG may justify a higher PE ratio.
  • A more expensive valuation may be justified as ZEG's earnings are expected to grow with 12.85% in the coming years.
PEG (NY)1.43
PEG (5Y)1.12
EPS Next 2Y13.43%
EPS Next 3Y12.85%

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 1.75%, ZEG has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 1.94, ZEG has a dividend in line with its industry peers.
  • ZEG's Dividend Yield is comparable with the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.75%

5.2 History

  • The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • ZEG pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • ZEG's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP52.89%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
ZEG.DE Yearly Income VS Free CF VS DividendZEG.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B
ZEG.DE Dividend Payout.ZEG.DE Dividend Payout, showing the Payout Ratio.ZEG.DE Dividend Payout.PayoutRetained Earnings

ASTRAZENECA PLC

FRA:ZEG (2/5/2026, 7:00:00 PM)

160.7

+0.95 (+0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-10
Inst Owners49.17%
Inst Owner ChangeN/A
Ins Owners0.02%
Ins Owner ChangeN/A
Market Cap498.26B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target175.52 (9.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.75%
Yearly Dividend2.53
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)5.49%
PT rev (3m)11.92%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)-0.46%
EPS NY rev (1m)2.29%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)0.43%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.57%
Valuation
Industry RankSector Rank
PE 20.76
Fwd PE 17.94
P/S 10.11
P/FCF 61.42
P/OCF 38.81
P/B 12.81
P/tB N/A
EV/EBITDA 29.47
EPS(TTM)7.74
EY4.82%
EPS(NY)8.96
Fwd EY5.57%
FCF(TTM)2.62
FCFY1.63%
OCF(TTM)4.14
OCFY2.58%
SpS15.9
BVpS12.55
TBVpS-3.7
PEG (NY)1.43
PEG (5Y)1.12
Graham Number46.75
Profitability
Industry RankSector Rank
ROA 8.21%
ROE 20.48%
ROCE 17.6%
ROIC 14.42%
ROICexc 16.02%
ROICexgc 81.56%
OM 24.34%
PM (TTM) 16.17%
GM 81.9%
FCFM 16.46%
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 3.41
Debt/EBITDA 1.34
Cap/Depr 84.97%
Cap/Sales 9.59%
Interest Coverage 10.83
Cash Conversion 73.11%
Profit Quality 101.79%
Current Ratio 0.88
Quick Ratio 0.69
Altman-Z 6.14
F-Score7
WACC9.13%
ROIC/WACC1.58
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y14.52%
EPS Next 2Y13.43%
EPS Next 3Y12.85%
EPS Next 5Y12.37%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.2%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.82%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%

ASTRAZENECA PLC / ZEG.DE FAQ

What is the fundamental rating for ZEG stock?

ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.


What is the valuation status of ASTRAZENECA PLC (ZEG.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.


What is the profitability of ZEG stock?

ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.


What is the valuation of ASTRAZENECA PLC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 20.76 and the Price/Book (PB) ratio is 12.81.


Can you provide the expected EPS growth for ZEG stock?

The Earnings per Share (EPS) of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 14.52% in the next year.